Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone781-547-7900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees14
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Ocugen (NASDAQ:OCGN) Frequently Asked Questions
What is Ocugen's stock symbol?
Ocugen trades on the NASDAQ under the ticker symbol "OCGN."
How were Ocugen's earnings last quarter?
Ocugen (NASDAQ:OCGN) posted its earnings results on Friday, August, 9th. The company reported ($1.80) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $1.20. View Ocugen's Earnings History.
When is Ocugen's next earnings date?
Has Ocugen been receiving favorable news coverage?
Press coverage about OCGN stock has trended negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ocugen earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Ocugen.
Who are some of Ocugen's key competitors?
Some companies that are related to Ocugen include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), Align Technology (ALGN), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Establishment Labs (ESTA), Sientra (SIEN) and Invacare (IVC).
What other stocks do shareholders of Ocugen own?
Who are Ocugen's key executives?
Ocugen's management team includes the folowing people:
- Dr. Shankar Musunuri Ph.D., MBA, Founder, Chairman & CEO
- Dr. Uday B. Kompella, Founder & Director
- Dr. Rasappa Arumugham, Chief Scientific Officer
- Ms. Kelly A. Beck M.B.A., P.M.P., SPHR, VP of Investor Relations & Admin.
- Dr. Daniel M. Jorgensen M.D., MPH, MBA, Chief Medical Officer
How do I buy shares of Ocugen?
Shares of OCGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ocugen's stock price today?
One share of OCGN stock can currently be purchased for approximately $2.15.
How big of a company is Ocugen?
Ocugen has a market capitalization of $3.40 million. The company earns $-8,640,000.00 in net income (profit) each year or ($47.31) on an earnings per share basis. Ocugen employs 14 workers across the globe.View Additional Information About Ocugen.
What is Ocugen's official website?
How can I contact Ocugen?
Ocugen's mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The company can be reached via phone at 781-547-7900 or via email at [email protected]
MarketBeat Community Rating for Ocugen (NASDAQ OCGN)
MarketBeat's community ratings are surveys of what our community members think about Ocugen and other stocks. Vote "Outperform" if you believe OCGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
